Effects of 12 weeks of probiotic supplementation on quality of life in colorectal cancer survivors: a double-blind, randomized, placebo-controlled trial.

Lee, Jee-Yon; Chu, Sang-Hui; Jeon, Justin Y; Lee, Mi-Kyung; Park, Ji-Hye; Lee, Duk-Chul; Lee, Ji-Won; Kim, Nam-Kyu
Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
2014Dec ; 46 ( 12 ) :1126-32.
저자 상세정보
Lee, Jee-Yon - Department of Family Medicine, Yonsei University, College of Medicine, Republic of Korea.
Chu, Sang-Hui - Department of Clinical Nursing Science, Yonsei University, College of Nursing, Nursing Policy Research Institute, Biobehavioural Research Center, Republic of Korea.
Jeon, Justin Y - Department of Sport and Leisure Studies, Sports Medicine Laboratory, Yonsei University, Republic of Korea.
Lee, Mi-Kyung - Department of Sport and Leisure Studies, Sports Medicine Laboratory, Yonsei University, Republic of Korea.
Park, Ji-Hye - Department of Sport and Leisure Studies, Sports Medicine Laboratory, Yonsei University, Republic of Korea.
Lee, Duk-Chul - Department of Family Medicine, Yonsei University, College of Medicine, Republic of Korea.
Lee, Ji-Won - Department of Family Medicine, Yonsei University, College of Medicine, Republic of Korea. Electronic address indi5645@yuhs.ac.
Kim, Nam-Kyu - Department of General Surgery, Yonsei University College of Medicine, Republic of Korea. Electronic address namkyuk@yuhs.ac.
ABSTRACT
BACKGROUND: Probiotics may help resolve bowel symptoms and improve quality of life. We investigated the effects of 12 weeks of probiotics administration in colorectal cancer patients.

METHODS: We conducted a double-blind, randomized, placebo-controlled trial. The participants took probiotics (Lacidofil) or placebo twice a day for 12 weeks. The cancer-related quality of life (FACT), patient's health-9 (PHQ-9), and bowel symptom questionnaires were completed by each participant.

RESULTS: We obtained data for 32 participants in the placebo group and 28 participants in the probiotics group. The mean ages of total participants were 56.18 짹 .86 years and 58.3% were male. Administration of probiotics significantly decreased the proportion of patients suffering from irritable bowel symptoms (0 week vs. 12 week; 67.9% vs. 45.7%, p=0.03), improved colorectal cancer-related FACT (baseline vs. 12 weeks: 19.79 짹 4.66 vs. 21.18 짹 3.67, p=0.04) and fatigue-related FACT (baseline vs. 12 weeks: 43.00 (36.50-45.50) vs. 44.50 (38.50-49.00), p=0.02) and PHQ-9 scores (0 weeks vs. 12 weeks; 3.00 (0-8.00) vs. 1.00 (0-3.00), p=0.01). We found significant differences in changes of the proportion of patients with bowel symptoms (p<0.05), functional well-being scores (p=0.04) and cancer-related FACT scores (p=0.04) between the two groups. CONCLUSION: Probiotics improved bowel symptoms and quality of life in colorectal cancer survivors. CI - Copyright ??2014 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.
keyword
Bowel symptoms; Cancer survivors; Colorectal cancer; Probiotics
MESH
Adult, Aged, Aged, 80 and over, Colorectal Neoplasms/*complications, Double-Blind Method, Female, Humans, Irritable Bowel Syndrome/etiology/*therapy, Male, Middle Aged, Probiotics/*therapeutic use, *Quality of Life, *Survivors, Treatment Outcome
링크

주제코드
주제명(Target field)
연구대상(Population)
연구참여(Sample size)
대상성별(Gender)
질병특성(Condition Category)
연구환경(Setting)
연구설계(Study Design)
연구기간(Period)
중재방법(Intervention Type)
중재명칭(Intervention Name)
키워드(Keyword)
유효성결과(Recomendation)
Administration of probiotics significantly decreased the proportion of patients suffering from irritable bowel symptoms (0 week vs. 12 week; 67.9% vs. 45.7%, p=0.03).
연구비지원(Fund Source)
근거수준평가(Evidence Hierarchy)
출판년도(Year)
참여저자수(Authors)
대표저자
DOI
10.1016/j.dld.2014.09.004
KCD코드
ICD 03
건강보험코드